Daily Intelligence Brief
Depo-Provera Filing Velocity Outpaces Entire Ozempic MDL Tenfold As Tylenol Autism Claims Resurge In New York
The Depo-Provera Products Liability Litigation (MDL 3140) (N.D. Fla., Judge M. Casey Rodgers) absorbed 450 new filings in the past week — more than ten times the volume of the Ozempic Gastroparesis Products Liability Litigation (MDL 3094) (E.D. Pa., Judge Karen Marston), which logged 43 new complaints. The Hair Relaxer Products Liability Litigation (MDL 3060) (N.D. Ill.) added 35 filings, while Tylenol Autism/ADHD Products Liability Litigation (MDL 3043) (S.D.N.Y.) showed unexpected resurgence with 7 new cases including Biggs v. Johnson & Johnson Consumer Inc. (1:26-cv-02536) — a notable uptick for a litigation that had slowed dramatically after Judge Denise Cote's Daubert exclusions. The NEC Formula Litigation (MDL 3026) (N.D. Ill.) also registered 5 scattered filings across Illinois, Arizona and Southern Illinois federal courts, suggesting coordinated counsel are testing alternative venues as the MDL approaches bellwether selection.Albany Diocese Settles Hundreds Of Child Sexual Abuse Cases In New York State Court
The Roman Catholic Diocese of Albany has reached a settlement resolving hundreds of child sexual abuse claims, marking one of the largest diocesan settlements in New York since the Child Victims Act revival window closed. The agreement covers claims brought under both the CVA and subsequent look-back legislation, with terms expected to influence pending church abuse litigation nationwide. The settlement arrives as bankruptcy courts have grown increasingly hostile to diocesan Chapter 11 strategies, following the Third Circuit's dismissal of the Boy Scouts plan and similar skepticism toward the LTL Management talc bankruptcy. For plaintiff attorneys, the Albany resolution demonstrates that state court aggregation — through coordinated filing and legislative pressure — can achieve results comparable to MDL mechanisms without federal centralization. The deal's structure and per-claimant economics will likely serve as a benchmark for the remaining New York dioceses still in litigation or bankruptcy proceedings.Cartiva Big Toe Implant MDL Sees First Post-Centralization Filing As Bellwether Selection Looms
The Cartiva Synthetic Cartilage Implant Products Liability Litigation (MDL 3172) (E.D.N.C., Judge Terrence W. Boyle) registered its first post-centralization filing with Bhatt v. Cartiva, Inc. (5:26-cv-00191), a development that signals the docket is beginning to attract coordinated counsel attention following the JPML's February 2026 transfer order. The MDL — which consolidates claims alleging the synthetic cartilage implant fails prematurely, requiring revision surgery — remains in its earliest stages with fewer than 50 actions currently pending. Judge Boyle has not yet issued a case management order establishing discovery protocols or bellwether selection criteria, creating a window for early entrants to shape the litigation's trajectory. The Cartiva device, marketed as an alternative to first metatarsophalangeal joint fusion for hallux rigidus, faces parallel scrutiny in state courts and adverse event reporting that plaintiff attorneys will likely leverage in upcoming expert discovery. Attorneys tracking emerging device MDLs should monitor Boyle's docket for the inaugural CMO, which will establish the timeline for initial disclosures and expert witness deadlines.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
